Status:
COMPLETED
Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
Researchers have designed a study medicine called bomedemstat (MK-3543) as a new way to treat certain rare blood diseases. The purpose of this study is to learn what happens to bomedemstat in a perso...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months before entering the study.
- Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2
- Medically healthy with no clinically significant medical history
Exclusion
- The main exclusion criteria include but are not limited to the following:
- History or presence of any of the following:
- Seizures
- Negative reactions in the blood system to any drugs
- Depression, unusual changes in mood or behavior or suicidal thoughts or behavior
- History of cancer
- Regular user of cannabis products within 6 months before entering the study.
- Unable to stop using or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days before entering the study.
Key Trial Info
Start Date :
October 2 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 11 2025
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT06596668
Start Date
October 2 2024
End Date
March 11 2025
Last Update
March 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion, Inc. ( Site 0001)
Tempe, Arizona, United States, 85283